Single Domain Antibody Development Service

Active

Contract Opportunity

COMBINED SYNOPSIS / SOLICITATION WORKFORM

1. Action Code: Combined Synopsis/Solicitation

1. Date: May 14


2. Year: 2026


3. Contracting Office Zip Code: 20817


4. Classification Code: 2651


5. Contracting Office Address:

6701 Rockledge Drive

Bethesda, MD 20817

1. Subject/Title: Single Domain Antibody Development Service


2. Solicitation Number: 26-003384


3. Closing Response Date: May 24, 2026 @ 9am. Eastern Daylight Time (EDT)


4. Contact Point(s): Towanda Daniels, Purchasing Agent


5. Contract Award Type: Firm Fixed Price


6. Brand Name or Equal Acquisition (FAR 52.211-6): No


7. Description:
   
   
   
   1. “This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a written solicitation will not be issued.”
   
   
   
   

1. The solicitation number and a statement that the solicitation is issued as a request for quote (RFQ).


2. The solicitation document, the incorporated provisions, and clauses are those in effect through Federal Acquisition Circular, FAC Number: 2026-01
   
   
   
   1. Effective Date: 03/13/2026
   
   
   
   


3. This solicitation is being released unrestricted. The NAICS code is 541714, and the small business size standard is 1000 employees. This acquisition is being conducted in accordance with the procedures of FAR Part 12 and FAR Part 13.


4. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has a requirement to generate a custom Single-Domain Antibody to the extracellular domain of the human Calcium-Sensing Receptor (CASR). This custom Single-Domain Antibody will enable the generation of a Variable Heavy-based injectable bioreagent specifically targeting the human Calcium-Sensing Receptor for use in parathyroid tumor Positron Emission Tomography -scanning, imaging, and localization and/or as a radiopharmaceutical treatment for inoperable parathyroid cancer (analogous to peptide receptor radionuclide therapy).

Required features of this purchase:

• 
  
  
  
  • 
    
    
    
    • Delivery of 0.5 to 1 mg each, of four (4) clones of purified, validated and 3XFLAG epitope-tagged sdAb (VHH)
    
    
    • Delivery of four (4) DNA minipreps, corresponding to independent clones of sdAb (VHH)
    
    
    • Complete protein and cDNA sequence information for the above sdAb (VHH)
    
    
    
    
  
  
  
  

The provisions at FAR Clause 52.212-1, Instructions to Offerors – Commercial Items, applies to this acquisition. The following addendum related to the Instructions to Offerors is included:

Addendum to FAR Clause 52.212-1, Instructions to Offerors – Commercial Items. Please refer to this addendum for additional attachments, including the Statement of Work and other relevant information.

Evaluations will be conducted in accordance with the provision at FAR Clause 52.212-2. Offerors will be evaluated as follows:

Evaluation-Commercial Items (Oct 2014)

1. The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers:

• 
  
  
  
  • Technical
  
  
  • Past Performance
  
  
  • Cost
  
  
  
  

All evaluation factors other than cost or price, when combined are significantly more important than cost or price.

Written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer’s specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award.

Please refer to the addendum for additional evaluation information.

Each Offeror must include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications – Commercial Items, with its offer.

Please note, each Offeror shall complete only paragraph (b) of this provision if the Offeror has completed the annual representations and certification electronically via the System for Award Management (SAM) website located at https://www.sam.gov/portal.

FAR Clause 52.212-4, Contract Terms and Conditions – Commercial Items, applies to this acquisition. The terms and conditions outlined in the following addendum also apply:

Addendum to FAR Clause 52.212-4, Contract Terms and Conditions – Commercial Items. Please refer to this addendum for additional terms and conditions related to the requirement.

FAR Clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders – Commercial Items, applies to this acquisition. The full text version of FAR 52.212-5 included in the addenda as Attachment 5 indicate which FAR clauses and provisions are applicable to this acquisition.

Contact Information:

Towanda Daniels

Email: danielt@mail.nih.gov

1. Place of Contract Performance: Bethesda, MD


2. Set-aside Status: Small

Attachments/Links